#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Epidemiology, Microbiology, Immunology / 2023 - 3

Monitoring hladiny protilátok v súvislosti s očkovaním proti SARS-CoV-2 – 11-mesačné sledovanie

Czech version

Authors: E. Miková 1;  K. Szabóová 2;  M. Bunčák 3;  E. Tibenská 2,4;  V. Štiglincová 1
Authors‘ workplace: Oddelenie virológie, sérológie a molekulárnej biológie infekčných ochorení, Medirex, a. s., Bratislava, Slovenská republika 1;  Oddelenie klinickej imunológie, Medirex, a. s., Bratislava, Slovenská republika 2;  Medirex, a. s., Bratislava, Slovenská republika 3;  Medirex group academy, Nitra, Slovenská republika 4
Published in: Epidemiol. Mikrobiol. Imunol. 72, 2023, č. 3, s. 127-139
Category: Original Papers

Overview

Aims: The primary aim of our monitoring was to determine the duration of persistence of antibody levels following administration of the Comirnaty (Pfizer/BioNTech) mRNA vaccine. The second aim was to analyse the effect of selected factors on the level of antibodies.

Methods: The study cohort consisted of 250 employees of the Medirex JSC laboratories. For the quantitative determination of specific IgG anti-S1 and anti-S2 antibodies to SARS-CoV-2, chemiluminescence immunoassay was used. Twenty-nine subjects were excluded from the analysis due to extreme values of antibody levels in individual measurements. The effect of gender, age, BMI, comorbidity, and adverse reactions after vaccination with the Comirnaty (Pfizer/BioNTech) mRNA vaccine on antibody levels was analysed. Comparisons were made for five samples collected from two weeks after the 1st dose to 36 weeks after the 2nd dose of the mRNA vaccine. After the fifth sampling, the cohort was divided into two groups. Group 1 received the 3rd dose, and Group 2 were controls. We performed the last (sixth) sample collection two weeks after booster administration in Group 1and 11 months after the 2nd dose of the vaccine in controls. Between months 8 and 10 after the 2nd dose, we performed a cellular immunity test.

Results: Altogether 99.6% of the participants had a positive antibody level at week 36. Antibodies were still present in controls at month 11 after the 2nd dose. Significantly higher antibody levels were found in females, younger subjects, and those with selected adverse reactions. Reactive specific T lymphocytes were present in 65.6% of the subjects between weeks 36 and 44.

Conslusion: The antibody response decreased with the time since the 2nd dose but was still present in the control group at week 48. The effect of booster on antibody levels was clearly demonstrated. We have not confirmed an association of cellular immunity with the level of antibodies or with the antibodies present.

Keywords:

antibody response dynamics – mRNA vaccine – age – gender – adverse effects – age – gender – adverse effects – mRNA vaccine – antibody response dynamics

Sources
  1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol, 2020;5(4):536–544.
  2. Zhou, P, Yang, XL, Wang, XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020;579:270–273.
  3. WHO: Coronavirus disease 2019 (COVID-19) Situation Report – 91, 2020. Dostupné na www: https://www.who.int/docs/ default-source/coronaviruse/situation-reports/20200420-sitrep-91-covid-19.pdf?sfvrsn=fcf0670b_10.
  4. Huang, C, Wang Y, Xingwang L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020;395:497–506.
  5. Wu Z, McGoogan JM. Characteristics of and important lessons From the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020;323(13):1239– 1242.
  6. Grigoryan L, Pulendran B. The immunology of SARS-CoV-2 infections and vaccines. Semin Immunol, 2020;50:101422.
  7. Post N, Eddy D, Huntley C, et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS One, 2020;15(12):e0244126.
  8. Kassambara A. Comparing multiple menas in R. Repeated measures ANOVA in R. Dostupné na www: https://www.datanovia. com/en/lessons/repeated-measures-anova-in-r/
  9. Diasorin [online]. LIAISON® SARS-CoV-2 S1/S2 IgG. Príbalová informácia, 2020. SK-200/007-797 Verzia 04-2020-05. Dostupné na www: https://www.diasorin.com/sites/default/files/allegati/ liaisonr_sars-cov-2_s1s2_igg_brochure.pdf.pdf.
  10. Qiagen® [online] QuantiFERON® SARS-CoV-2 ELISA Kit. Príbalová informácia 2021-11,Verzia 1. Dostupné na www: https:// www.qiagen.com/de/resources/resourcedetail?id=3d27842e- c811-442c-bcad-a9d42945e59c&lang=en.
  11. Lustig Y, Sapir E, Regev-Yochay G, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med, 2021;9:999–1009.
  12. Pellini R, Venuti A, Pimpinelli F, et al. Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMedicine, 2021;36:100928.
  13. Di Resta Ch, Ferrari D, Vigano M, et al. The gender impact assesment among healthcare workers in the SARS-CoV-2 vaccination – an analysis of serological response and side effects. Vaccines, 2021;9:22.
  14. Naaber P, Tserel L, Kangroo K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. The Lancet Regional Health – Europe, 2021;10:100208
  15. Speletas M, Voulgaridi I, Sarrou S, et al. Intensity and Dynamics of Anti-SARS-CoV-2 Immune Responses after BNT162b2 mRNA Vaccination: Implications for Public Health Vaccination Strategies. Vaccines, 2022;10:316.
  16. Rechavi Y, Shashar M, Lellouche J, et al. Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response. Vaccines, 2021;9:977.
  17. Silva JO, Reis T, Lopes C, et al. Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers. Vaccine, 2022;40:650–655.
  18. Azzolini E, Canziani, LM, Voza A, et al. Short-Term Adverse Events and Antibody Response to the BNT162b2 SARS-CoV-2 Vaccine in 4156 Health Care Professionals. Vaccines, 2022;10:439.
  19. Coggins SAA, Laing ED, Olsen CH, et al. Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers. Open Forum Infect Dis, 2021;9(1): 575.
  20. Watanabe M, Balena A, Tuccinardi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab Res Rev, 2022;38(1):e3465.
  21. Malavazos AE, Basilico S, Iacobellis G, et. al. Antibody responses to BNT162b2 mRNA vaccine: Infection-naïve individuals with abdominal obesity warrant attention. Obesity (Silver Spring), 2022;30(3):606–613.
  22. Costa C, Migliore E, Galassi C, et al. Factors Influencing Level and Persistence of Anti SARS-CoV-2 IgG after BNT162b2 Vaccine: Evidence from a Large Cohort of HealthcareWorkers. Vaccines, 2022;10:474.
  23. Vassilaki N, Gargalionis AN, Bletsa A, et al. Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare Workers. Microorganisms, 2021;9(8):1725.
  24. Terpos E, Trougakos IP, Apostolakou F, et al. Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. Am J Hematol, 2021;96(7):E257–E259.
  25. Levin EG., Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med, 2021;385(24):e84.
  26. Pilmis B, Elkaibi I, Péan de Ponfilly G, et al. Evolution of antiSARS-CoV-2 immune response in a cohort of French healthcare workers followed for 7 months. Infect Dis Now, 2022;52(2):68–74.
  27. Infantino M, Pieri M, Nuccetelli M, et al. The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays. International Immunopharmacology, 2021;100:108095.
  28. Müller L, Kannenberg J, Biemann R, et al. Comparison of the measured values of quantitative SARS-CoV-2 spike antibody assays. Journal of Clinical Virology, 2022;155:105269.
  29. Kobayashi R, Suzuki E, Murai R, et al. Performance analysis among multiple fully automated anti-SARS-CoV-2 antibody measurement reagents: A potential indicator for the correlation of protection in the antibody titer. Journal of Infection and Chemotherapy, 2022;28:1295–1303
Labels
Hygiene and epidemiology Medical virology Clinical microbiology
The role of endogenous retroviruses in the human body
Mycobacteriosis: the most common causative agents
Extracellular vesicles in infectious diseases – importance and perspectives
Increasing prevalence of celiac disease – where to look for answers?
Human babesiosis
Detection of superantigens in Streptococcus pyogenes isolates based on whole genome sequencing data
The prevalence of methicillin-resistant Staphylococcus aureus among nursing home residents for the elderly in Slovakia
Vzpomínka na RNDr. Václava Rupeše, CSc.
Article was published in

Epidemiology, Microbiology, Immunology

Issue 3
2023 Issue 3
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#